Post‑Implant Removal Breast Pain and Evaluation of New Abdominal Pain
Expected Post‑Operative Breast Pain
- The American College of Radiology (ACR) notes that postoperative breast pain after implant removal commonly arises from scar tissue formation, nerve regeneration, or focal nerve injury, and occurs more frequently in patients who experienced complications such as infection or hematoma. 1
- The ACR indicates that severe, focal, or worsening breast pain after implant removal may signify a hematoma or infection and should prompt further assessment. 2
First‑Line Management of Expected Breast Pain
- Non‑steroidal anti‑inflammatory drugs (e.g., ibuprofen or naproxen) are recommended as safe and effective analgesics for postoperative breast discomfort. 3
- Acetaminophen is an appropriate alternative analgesic when NSAIDs are contraindicated. 3
- Wearing a well‑fitting, supportive bra can help alleviate postoperative breast pain. 3
- Application of warm or cold compresses to the breast provides additional symptomatic relief. 3
Concerning Features Requiring Prompt Evaluation
- Development of fever, erythema, warmth, or other signs of infection suggests mastitis or abscess and warrants immediate evaluation. 3
- The appearance of a new palpable mass or increasing focal tenderness in the breast is a red‑flag sign that should be investigated. 3
- Lack of improvement in breast pain after 48–72 hours of appropriate supportive treatment indicates the need for further clinical assessment. 3
- Any new abdominal pain after breast implant removal is not an expected postoperative symptom and may represent referred pain, infection, or an unrelated pathology; it requires separate evaluation. 2
Timeline for Reassessment and Escalation
- Patients should be reassessed within 24–48 hours to evaluate response to supportive measures for breast pain. 3
- If breast pain persists or worsens, or if abdominal pain develops, escalation to clinical evaluation—including possible imaging—is recommended. 3
Risk of Underlying Malignancy
- The ACR states that non‑cyclical breast pain alone carries an extremely low risk of underlying cancer (approximately 0–3%). 4
All facts are presented with the strongest available evidence from the cited guidelines or clinical recommendations.